rs2295080 — MTOR

Promoter variant that reduces mTOR expression; the G allele lowers mTOR transcriptional activity and is associated with decreased cancer risk across multiple tumor types

See your personal result for MTOR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MTOR rs2295080 — The Longevity Pathway's Genetic Dimmer Switch

mTOR (mechanistic target of rapamycin) is arguably the most powerful longevity-relevant kinase in human biology. It integrates signals from nutrients, amino acids, growth factors, and energy status to control cell growth, protein synthesis, and — critically — autophagy11 autophagy
the cellular garbage-disposal process that clears damaged proteins and organelles; inhibition of mTOR is the primary trigger for autophagy induction. When mTOR activity is chronically high, cells prioritize growth and suppress the housekeeping functions that prevent aging; when mTOR is appropriately restrained, autophagy runs, senescent cells are cleared, and lifespan extends across every organism where this has been tested.

The rs2295080 T>G variant sits in the promoter of the MTOR gene on chromosome 1 and acts as a functional dimmer switch for mTOR expression. Individuals carrying the G allele have measurably lower MTOR mRNA levels in their tissues, confirmed by luciferase reporter assays showing the G allele significantly decreases promoter transcriptional activity. The G allele essentially dials mTOR expression down22 The G allele essentially dials mTOR expression down
Cao Q et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLOS One, 2012.

The Mechanism

rs2295080 is located approximately 2 kb upstream of the MTOR coding sequence, placing it in the core promoter region that controls transcription initiation. The T→G change alters a transcription factor binding site, reducing the efficiency with which the transcriptional machinery assembles and initiates MTOR mRNA production. The result is a genotype-dependent gradient of mTOR activity: TT > GT > GG.

Lower constitutive mTOR expression has several downstream effects. mTORC1 (the nutrient-sensing complex) phosphorylates S6 kinase and 4E-BP1 to drive protein synthesis; when this activity is reduced, cells shift resources toward protein quality control and autophagy induction. mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested33 mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested
Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging, 2023. Genetic lower expression via rs2295080 may mimic, in a modest and constitutive way, the longevity biology of intermittent mTOR suppression.

The Evidence

The primary evidence base for rs2295080 consists of cancer risk studies, which are the clearest functional readout of mTOR overactivity: elevated mTOR drives cell proliferation and suppresses apoptosis, so genotypes with higher mTOR expression should show elevated cancer susceptibility.

Gastric cancer (n=1,607)44 Gastric cancer (n=1,607)
Xu M et al. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLOS One, 2013: the G allele was associated with a 23% lower risk of gastric cancer (OR 0.77, 95% CI 0.65–0.92, P=0.004).

Colorectal cancer (n=1,514)55 Colorectal cancer (n=1,514)
Xu M et al. Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population. Biomed Pharmacother, 2015: carriers of TG or GG genotypes had a 24% lower risk of colorectal cancer (OR 0.76, 95% CI 0.62–0.94, P=0.011); the effect was stronger in men and the elderly (OR 0.63 and 0.66, respectively).

Renal cell cancer (n=1,470)66 Renal cell cancer (n=1,470)
Cao Q et al. 2012: the G allele was associated with reduced RCC risk (OR 0.74, 95% CI 0.59–0.91, P=0.005).

Breast cancer (n=1,143)77 Breast cancer (n=1,143)
Zhao Y et al. 2016: GG homozygotes had a 55% lower breast cancer risk (OR 0.45, 95% CI 0.23–0.91, P=0.02) and lower rates of lymph node metastasis.

A comprehensive meta-analysis of 18 Chinese studies88 A comprehensive meta-analysis of 18 Chinese studies
Qi GH et al. 2020 confirmed decreased risk for urinary system tumors and prostate cancer (heterozygote OR 0.80, P<0.001), while noting a paradoxical increased leukemia risk in GG homozygotes — a finding that requires further study and likely reflects cancer-type-specific mTOR biology.

Most studies have been conducted in Chinese populations; replication in European and other populations is warranted, which is reflected in the moderate evidence rating.

Practical Actions

The actionable implications of rs2295080 center on how your genotype shapes the ideal strategy for managing mTOR activity over time. Regardless of genotype, mTOR is suppressed by fasting, protein restriction, and exercise, and activated by dietary protein (especially leucine/BCAAs), insulin, and growth factors. But the baseline level of MTOR expression differs by genotype, which affects how aggressively these lifestyle tools need to be applied.

TT carriers have higher constitutive mTOR activity — they benefit most from deliberate mTOR-suppression protocols: extended overnight fasting (14–16 hours), periodic protein cycling (low protein days), and close attention to protein timing relative to meals. GT carriers have an intermediate baseline and similar considerations at lower urgency. GG carriers enjoy naturally lower mTOR expression, meaning their cells engage autophagy more readily, but they may also need to ensure adequate protein intake to support muscle protein synthesis since mTOR plays a key anabolic role.

Interactions

rs2295080 is part of the broader PI3K-AKT-mTOR signaling axis. Related SNPs worth considering include rs2536 (another mTOR variant studied for cancer risk), and upstream regulators like variants in PTEN (which normally suppresses AKT/mTOR activity) and AMPK pathway genes. FOXO3A (rs2802292) operates in the same longevity signaling network: FOXO3 is normally phosphorylated and inactivated by AKT downstream of mTOR, so G-allele carriers at both rs2295080 (lower mTOR) and rs2802292 (higher stress-induced FOXO3 expression) would be expected to have complementary longevity biology through this pathway. This interaction is biologically plausible but has not been formally tested in a combined genotype study.

Genotype Interpretations

What each possible genotype means for this variant.

GG Low mTOR Expresser Beneficial

Genetically lower mTOR promoter activity — consistent with reduced cancer risk and enhanced autophagy capacity

GG homozygotes have the lowest constitutive MTOR expression of the three genotypes. From a longevity biology perspective, this means cells are predisposed toward autophagy engagement and away from unchecked proliferative signaling — a profile that mimics, at least partially, the pharmacological effects of rapamycin.

One notable caveat: in studies of acute leukemia, the GG genotype showed a paradoxically elevated risk (OR around 2.0–2.25), likely because some blood cancers may actually depend on reduced mTOR activity for their survival or evasion of apoptosis. This cancer-type-specific reversal is biologically plausible and is a known complexity in mTOR biology. GG carriers should not interpret their genotype as universally protective against all malignancies.

For metabolic reasons, GG carriers should also pay attention to protein intake and leucine adequacy — because mTOR-driven anabolic signaling is somewhat blunted, they may need to be more deliberate about ensuring adequate complete protein intake to maintain muscle mass, especially with aging.

GT Intermediate mTOR Intermediate

One copy of the lower-activity G allele — moderate reduction in mTOR expression with partial cancer-protective effect

The GT genotype places you in an intermediate zone for mTOR pathway activity. In the dominant model (TG/GG vs TT), GT carriers together with GG carriers show approximately 20–24% lower cancer risk compared to TT homozygotes across gastric, colorectal, and renal cancers.

From a practical standpoint, the GT genotype means your cells have somewhat more mTOR activity than GG carriers but less than TT. This affects the balance between anabolic (growth, protein synthesis) and catabolic (autophagy, protein recycling) cellular states. Intermittent fasting and periodic protein cycling provide the clearest benefits for GT carriers — they add deliberate mTOR suppression on top of a partially restrained genetic baseline.

TT High mTOR Expresser High Risk

Higher constitutive mTOR expression from two T alleles — elevated cancer risk signals and reduced baseline autophagy

The TT genotype represents the highest baseline mTOR activity in this promoter variant system. mTOR's role in cancer biology is well-established: excessive mTORC1 signaling drives cell growth via S6K1 and 4E-BP1 phosphorylation, inhibits autophagy (removing the tumor-suppressive housekeeping function), and promotes translation of oncoproteins like cyclin D1 and c-Myc. Sustained high mTOR activity also contributes to cellular senescence and mitochondrial dysfunction — the same mechanisms that accelerate aging.

Importantly, TT carriers are not destined for cancer or premature aging — this is a risk modifier, not a deterministic mutation. But the variant does indicate that lifestyle strategies to suppress mTOR activity deserve high priority. Intermittent fasting, protein cycling, and exercise-induced AMPK activation are the most evidence-supported behavioral tools to counteract elevated mTOR tone. Monitoring metabolic health markers is also warranted given the atherosclerosis associations.